S05 - How Obesity Weighs-in on Management of T2D with Co-Morbid ASCVD and/or Heart Failure

Saturday, August 9, 2025

10:00 AM - 10:45 AM MST

CE/CME Hours: .75 CE

Pharmacology Hours: .75 CE
Universal Activity Number (Live): JA4008258-0000-25-118-L01-P

Visceral adiposity/obesity are root causes for insulin resistance and T2D. Additionally, obesity is an independent risk factor for both atherosclerotic heart disease and heart failure. Advanced Diabetes Managers who address these co-morbid conditions must understand bi-directional relationships and the recommended pharmacological treatments to optimize care. This session discusses the ADA recommendations for disease management of those with obesity, T2D, ASCVD and/or heart failure. The presenter uses case studies to illustrate implementation into practice.

Disclosure(s):

Lucia M. Novak, MSN, ANP-BC, BC-ADM: Abbott Diabetes Care: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Nestle: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Sanofi: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing)

Primary Presenter(s)

Lucia M. Novak, MSN, ANP-BC, BC-ADM (she/her/hers)

President
Diabesity, LLC

Disclosure(s): Abbott Diabetes Care: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Nestle: Speakers' Bureau (Ongoing); Novo Nordisk: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing); Sanofi: Consultant / Advisory Board (Ongoing), Speakers' Bureau (Ongoing)

Session Host(s)

Cassandra E. Henderson, MD, MSc (she/her/hers)

Maternal Fetal Medicine and Diabetologist
Rockwood Partners, LLC